POSB135 Budget Impact Analysis of Brigatinib for First-line Treatment of Alk-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Italy
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.408
https://www.valueinhealthjournal.com/article/S1098-3015(21)02203-8/fulltext
Title :
POSB135 Budget Impact Analysis of Brigatinib for First-line Treatment of Alk-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Italy
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02203-8&doi=10.1016/j.jval.2021.11.408
First page :
Section Title :
Open access? :
No
Section Order :
11185